美国医疗保健新闻

有$1,000?2022年及以后可能成为便宜货的2只股票

有$1,000?2022年及以后可能成为便宜货的2只股票

As 2022 draws to a close, it is safe to say Wall Street won’t remember this year fondly. Economic problems such as inflation, a persistent pandemic, and geopolitical tensions are some factors contributing to the broader market’s poor performance this year. No one can predict when equities will recover, but when they do, it will pay to have skin in the game.

Buying undervalued stocks today could help investors beat the market in the next five years and beyond. Let’s look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) Gilead Sciences (NASDAQ: GILD) .

继续阅读

更多细节见。

有$1,000?2022年及以后可能成为便宜货的2只股票

相关文章

回到顶部按钮